🇺🇸 FDA
Patent

US 11723922

CXCR6-transduced T cells for targeted tumor therapy

granted A61KA61K40/11A61K40/4219

Quick answer

US patent 11723922 (CXCR6-transduced T cells for targeted tumor therapy) held by Ludwig-Maximilians-Universitat Munchen expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ludwig-Maximilians-Universitat Munchen
Grant date
Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K40/11, A61K40/4219, A61P, A61P35/00